7/28/2011

Trius Therapeutics will gain as much as $94 million, including $25 million upfront, in a licensing pact with Bayer HealthCare for torezolid phosphate, a late-stage drug candidate for bacterial infection, including methicillin-resistant Staphylococcus aureus.

Related Summaries